649 active
/
1255 total (since 2015)
343
Phase 1 Active
720 total
351
Phase 2 Active
654 total
71
Phase 3 Active
114 total
6
Phase 4 Active
8 total
Top Sponsors (Industry)
Sorted by active Active Done Failed
AbbVie 7 7 7
Taiho Oncology, Inc. 5 0 1
Kura Oncology, Inc. 4 0 0
Syndax Pharmaceuticals 3 1 0
Orca Biosystems, Inc. 3 0 0
Ryvu Therapeutics SA 3 0 0
Novartis 2 3 8
Johnson & Johnson 2 1 1
Daiichi Sankyo 2 1 1
Lomond Therapeutics Holdings, Inc. 2 1 0
Actinium Pharmaceuticals 2 0 1
Bio-Path Holdings, Inc. 2 0 1
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 2 0 1
Bristol-Myers Squibb 2 0 0
Sichuan Baili Pharmaceutical Co., Ltd. 2 0 0
NCT05316701 ACTIVE NOT RECRUITING
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc. n=187
NCT04628026 RECRUITING
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
University of Ulm n=650
NCT07407140 NOT YET RECRUITING
VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML
Institute of Hematology & Blood Diseases Hospital, China n=300
NCT07132684 RECRUITING
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
Institute of Hematology & Blood Diseases Hospital, China n=240
NCT07022678 NOT YET RECRUITING
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Children's Oncology Group n=556
NCT07007312 RECRUITING
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology, Inc. n=1,300
NCT04293562 RECRUITING
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Children's Oncology Group n=1,186
NCT03844048 ACTIVE NOT RECRUITING
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie n=165
NCT07425808 NOT YET RECRUITING
FLT3-ITD Targeted Therapy in Fit AML Patients
European Organisation for Research and Treatment of Cancer - EORTC n=230
NCT03480360 ACTIVE NOT RECRUITING
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center n=21
NCT04708054 RECRUITING
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
M.D. Anderson Cancer Center n=324
NCT07407660 NOT YET RECRUITING
Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax
Peking University People's Hospital n=250
NCT06713837 RECRUITING
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS n=339
NCT03182244 ACTIVE NOT RECRUITING
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
Astellas Pharma Inc n=276
NCT07211958 RECRUITING
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Syndax Pharmaceuticals n=468
NCT04256317 RECRUITING
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology, Inc. n=236
NCT05429632 RECRUITING
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Priothera SAS n=366
NCT07366801 RECRUITING
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=64
NCT03701308 ACTIVE NOT RECRUITING
Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
National Cancer Institute (NCI) n=267
NCT05183035 RECRUITING
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
PedAL BCU, LLC n=98
NCT05457556 ACTIVE NOT RECRUITING
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
Children's Oncology Group n=435
NCT06788756 RECRUITING
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Moleculin Biotech, Inc. n=312
NCT07264010 NOT YET RECRUITING
Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study
Nanfang Hospital, Southern Medical University n=87
NCT07255872 NOT YET RECRUITING
A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia
Sichuan Baili Pharmaceutical Co., Ltd. n=80
NCT06389292 RECRUITING
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Ascentage Pharma Group Inc. n=486
NCT07232134 RECRUITING
The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=100
NCT03173248 ACTIVE NOT RECRUITING
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Institut de Recherches Internationales Servier n=146
NCT07223814 NOT YET RECRUITING
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Stichting Hemato-Oncologie voor Volwassenen Nederland n=875
NCT04229979 ACTIVE NOT RECRUITING
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
Sellas Life Sciences Group n=127
NCT07157514 NOT YET RECRUITING
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
Actinium Pharmaceuticals n=306
NCT04102020 ACTIVE NOT RECRUITING
A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
AbbVie n=112
NCT07075016 RECRUITING
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Stichting Hemato-Oncologie voor Volwassenen Nederland n=227
NCT02993523 ACTIVE NOT RECRUITING
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
AbbVie n=443
NCT06387069 RECRUITING
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Hutchmed n=316
NCT06990321 RECRUITING
Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia
Yehui Tan n=68
NCT05994690 RECRUITING
CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients
Princess Maxima Center for Pediatric Oncology n=905
NCT02521493 ACTIVE NOT RECRUITING
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Children's Oncology Group n=280
NCT03897127 ACTIVE NOT RECRUITING
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
University of Ulm n=882
NCT06744504 RECRUITING
Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1
Institute of Hematology & Blood Diseases Hospital, China n=300
NCT05356169 ACTIVE NOT RECRUITING
Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China n=312
NCT03021330 ACTIVE NOT RECRUITING
Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML
Institute of Hematology & Blood Diseases Hospital, China n=1,100
NCT06972641 RECRUITING
Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation
Ruijin Hospital n=126
NCT05907057 RECRUITING
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
Servier Affaires Médicales n=245
NCT06652438 RECRUITING
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Stichting Hemato-Oncologie voor Volwassenen Nederland n=415
NCT03507842 ENROLLING BY INVITATION
A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML.
Asan Medical Center n=380
NCT04314219 RECRUITING
Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients
King Faisal Specialist Hospital & Research Center n=264
NCT05991908 RECRUITING
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
Shanghai Jiao Tong University School of Medicine n=222
NCT05674539 ENROLLING BY INVITATION
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology n=200
NCT06810791 RECRUITING
HVA vs IA/DA or VA in the Treatment of ND HR-AML
Nanfang Hospital, Southern Medical University n=876
NCT06802718 RECRUITING
Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia
Peking University People's Hospital n=96
NCT05153226 ACTIVE NOT RECRUITING
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
DKMS gemeinnützige GmbH n=640
NCT05477589 RECRUITING
Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML
Vastra Gotaland Region n=170
NCT04027309 ACTIVE NOT RECRUITING
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
Stichting Hemato-Oncologie voor Volwassenen Nederland n=777
NCT04168502 RECRUITING
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
Gruppo Italiano Malattie EMatologiche dell'Adulto n=414
NCT05726110 RECRUITING
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Shanxi Bethune Hospital n=50
NCT05177731 ACTIVE NOT RECRUITING
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML
Chen Suning n=188
NCT03839771 ACTIVE NOT RECRUITING
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
Stichting Hemato-Oncologie voor Volwassenen Nederland n=968
NCT06613035 NOT YET RECRUITING
Twice-per-weekSelinexor, 2 Days Melphalan
Institute of Hematology & Blood Diseases Hospital, China n=126
NCT06475820 ACTIVE NOT RECRUITING
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=150
NCT02416388 RECRUITING
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
University Hospital, Angers n=3,100
NCT06297772 NOT YET RECRUITING
Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR
Ruijin Hospital n=220
NCT06418776 RECRUITING
IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML
National Research Center for Hematology, Russia n=198
NCT04173533 ACTIVE NOT RECRUITING
Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT
University of Birmingham n=326
NCT05686538 RECRUITING
Innate Donor Effector Allogeneic Lymphocyte Infusion After Stem Cell Transplantation: the IDEAL Trial
Rigshospitalet, Denmark n=80
NCT05939180 RECRUITING
VA vs DA for Newly Diagnosed Hig-risk AML
The First Affiliated Hospital of Soochow University n=116
NCT06182592 NOT YET RECRUITING
A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. n=120
NCT05313958 RECRUITING
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=43
NCT02665065 ACTIVE NOT RECRUITING
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Actinium Pharmaceuticals n=153
NCT05876832 NOT YET RECRUITING
A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)
Shijiazhuang Yiling Pharmaceutical Co. Ltd n=312
NCT05805098 RECRUITING
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
The First Affiliated Hospital of Soochow University n=60
NCT05404906 RECRUITING
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
The First Affiliated Hospital of Soochow University n=124
NCT02730299 COMPLETED
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Gamida Cell ltd n=125
NCT03594149 COMPLETED
Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients
Centre Henri Becquerel n=60
NCT04161885 TERMINATED
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie n=465
NCT03069352 COMPLETED
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
AbbVie n=211
NCT02752035 COMPLETED
A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
Astellas Pharma Global Development, Inc. n=183
NCT05054543 TERMINATED
Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
Apollomics Inc. n=140
NCT03765541 TERMINATED
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia
University Hospital, Toulouse n=73
NCT05079230 TERMINATED
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
Gilead Sciences n=378
NCT04778397 TERMINATED
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
Gilead Sciences n=258
NCT02997202 COMPLETED
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Astellas Pharma Global Development, Inc. n=356
NCT03092674 COMPLETED
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI) n=76
NCT02920008 COMPLETED
Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Astex Pharmaceuticals, Inc. n=302
NCT03306264 COMPLETED
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
Astex Pharmaceuticals, Inc. n=227
NCT03275636 COMPLETED
Haploidentical Donor vs mMUD in Hematological Malignancies
DKMS gemeinnützige GmbH n=98
NCT02668653 COMPLETED
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
Daiichi Sankyo n=539
NCT03616470 TERMINATED
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
GlycoMimetics Incorporated n=388
NCT04571645 TERMINATED
Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia
Jazz Pharmaceuticals n=9
NCT03379727 COMPLETED
Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.
Novartis Pharmaceuticals n=301
NCT02473146 COMPLETED
Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4
Versailles Hospital n=225
NCT02461537 COMPLETED
Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML
DKMS gemeinnützige GmbH n=281
NCT05020665 TERMINATED
Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML
Kronos Bio n=15
NCT04842604 COMPLETED
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
Pfizer n=14
NCT03699475 TERMINATED
Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS
Bellicum Pharmaceuticals n=1
NCT03512197 COMPLETED
A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
Novartis Pharmaceuticals n=511
NCT03719534 COMPLETED
Haplo HCT vs Haplo-cord HCT for Patients With AML
The First Affiliated Hospital of Soochow University n=134
NCT03941964 COMPLETED
A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
AbbVie n=60
NCT04326764 TERMINATED
Panobinostat Maintenance After HSCT fo High-risk AML and MDS
Goethe University n=52
NCT04095858 TERMINATED
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) n=11
NCT03504410 TERMINATED
Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML
Cornerstone Pharmaceuticals n=200
NCT03389724 COMPLETED
Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia
Children's Cancer Hospital Egypt 57357 n=245
NCT04093505 TERMINATED
Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)
University Hospital Heidelberg n=28
NCT04676243 WITHDRAWN
Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML
University Hospital Heidelberg
NCT02999854 TERMINATED
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer
Kiadis Pharma n=63
NCT04509622 COMPLETED
A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)
AbbVie n=14
NCT02927938 TERMINATED
Leukemia Stem Cell Detection in Acute Myeloid Leukemia
Wake Forest University Health Sciences n=18
NCT03151408 TERMINATED
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Helsinn Healthcare SA n=406
NCT02298166 TERMINATED
Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
University of Ulm n=9
NCT03825887 COMPLETED
Nalbuphine Versus Morphine for Mucositis Pain in Pediatric Cancer Patients
Children's Cancer Hospital Egypt 57357 n=80
NCT03066466 WITHDRAWN
Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT
Loyola University
NCT02870777 COMPLETED
MRD-directed Therapy for Low-risk and Intermediate-risk AML.
Nanfang Hospital, Southern Medical University n=743
NCT02671708 COMPLETED
IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT
Nanfang Hospital, Southern Medical University n=153
NCT02474290 COMPLETED
Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML
Nanfang Hospital, Southern Medical University n=202
NCT02785900 TERMINATED
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Seagen Inc. n=240
NCT05554393 RECRUITING
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
NCT04284787 ACTIVE NOT RECRUITING
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT05564390 RECRUITING
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
National Cancer Institute (NCI)
NCT06954987 NOT YET RECRUITING
Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
NCT07053020 NOT YET RECRUITING
A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
NCT05554419 NOT YET RECRUITING
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
NCT06672146 RECRUITING
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
NCT04214249 ACTIVE NOT RECRUITING
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT06917911 NOT YET RECRUITING
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
NCT07153497 NOT YET RECRUITING
Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
National Cancer Institute (NCI)
NCT05554406 RECRUITING
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
NCT07437950 NOT YET RECRUITING
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
NCT06317649 RECRUITING
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
NCT03289910 ACTIVE NOT RECRUITING
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
NCT03849651 ACTIVE NOT RECRUITING
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
NCT05520567 ACTIVE NOT RECRUITING
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
Astellas Pharma Global Development, Inc.
NCT06483906 RECRUITING
Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT06511882 RECRUITING
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
H. Lee Moffitt Cancer Center and Research Institute
NCT06664879 ACTIVE NOT RECRUITING
ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial
M.D. Anderson Cancer Center
NCT06904482 RECRUITING
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
Case Comprehensive Cancer Center
NCT06969430 RECRUITING
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
Debiopharm International SA
NCT07437170 ACTIVE NOT RECRUITING
Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML
The Children's Hospital of Zhejiang University School of Medicine
NCT04195633 RECRUITING
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
NCT06284486 RECRUITING
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
M.D. Anderson Cancer Center
NCT06052813 ACTIVE NOT RECRUITING
A Study of BN104 in the Treatment of Acute Leukemia
Institut de Recherches Internationales Servier (I.R.I.S.)
NCT05580601 RECRUITING
Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)
Children's Hospital Medical Center, Cincinnati
NCT06773208 RECRUITING
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center
NCT05589896 RECRUITING
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
NCT06782542 RECRUITING
Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
Justin Watts, MD
NCT07425782 NOT YET RECRUITING
Venetoclax Combined With Azacitidine for Consolidation Therapy in AML
The First Affiliated Hospital of Soochow University
NCT03629171 RECRUITING
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT05428969 ACTIVE NOT RECRUITING
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
Faron Pharmaceuticals Ltd
NCT03672539 ACTIVE NOT RECRUITING
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT07423104 NOT YET RECRUITING
A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia
University of Rochester
NCT02835222 ACTIVE NOT RECRUITING
Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients
Wake Forest University Health Sciences
NCT04746235 ACTIVE NOT RECRUITING
Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT05010122 RECRUITING
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT07410494 RECRUITING
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Essen Biotech
NCT04726241 RECRUITING
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
PedAL BCU, LLC
NCT02861417 ACTIVE NOT RECRUITING
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
NCT03383575 RECRUITING
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04065399 RECRUITING
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Syndax Pharmaceuticals
NCT03147612 ACTIVE NOT RECRUITING
Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT06158828 RECRUITING
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
Washington University School of Medicine
NCT05197426 ACTIVE NOT RECRUITING
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
Bristol-Myers Squibb
NCT06611839 RECRUITING
Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
Institute of Hematology & Blood Diseases Hospital, China
NCT07392970 NOT YET RECRUITING
Motixafortide for MRD Sensitization in AML
Washington University School of Medicine
NCT07392242 RECRUITING
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
NCT07148180 RECRUITING
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Jacqueline Garcia, MD
NCT06001385 ACTIVE NOT RECRUITING
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Center for International Blood and Marrow Transplant Research
NCT07259707 RECRUITING
Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML
First Affiliated Hospital of Zhejiang University
NCT07172204 RECRUITING
Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
First Affiliated Hospital of Zhejiang University
NCT03059485 ACTIVE NOT RECRUITING
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission
Beth Israel Deaconess Medical Center
NCT05092451 ACTIVE NOT RECRUITING
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
NCT05732103 RECRUITING
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Chordia Therapeutics, Inc.
NCT05917405 RECRUITING
Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT
Nantes University Hospital
NCT07046078 RECRUITING
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Fred Hutchinson Cancer Center
NCT06660368 RECRUITING
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
H. Lee Moffitt Cancer Center and Research Institute
NCT02935361 ACTIVE NOT RECRUITING
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
University of Southern California
NCT03164057 ACTIVE NOT RECRUITING
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
NCT07372885 NOT YET RECRUITING
GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia
University of Manchester
NCT03737955 RECRUITING
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
University of Washington
NCT04262843 ACTIVE NOT RECRUITING
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia
City of Hope Medical Center
NCT07370064 NOT YET RECRUITING
Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia
Xuzhou Medical University
NCT04994808 ACTIVE NOT RECRUITING
Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
NCT05442216 RECRUITING
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
Joshua Zeidner
NCT06013423 RECRUITING
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Fred Hutchinson Cancer Center
NCT07228273 RECRUITING
Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
OHSU Knight Cancer Institute
NCT07356154 RECRUITING
A Study of Revumenib and Mezigdomide in People With Leukemia
Memorial Sloan Kettering Cancer Center
NCT04811560 RECRUITING
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Janssen Research & Development, LLC
NCT04062266 ACTIVE NOT RECRUITING
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
M.D. Anderson Cancer Center
NCT03121014 ACTIVE NOT RECRUITING
Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes
University of Illinois at Chicago
NCT03862157 ACTIVE NOT RECRUITING
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT03661307 RECRUITING
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT06456463 RECRUITING
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
Stemline Therapeutics, Inc.
NCT04686682 RECRUITING
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Jacobio Pharmaceuticals Co., Ltd.
NCT04203316 ACTIVE NOT RECRUITING
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
Children's Oncology Group
NCT04644016 RECRUITING
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Memorial Sloan Kettering Cancer Center
NCT07304011 RECRUITING
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
University of California, Davis
NCT03674411 ACTIVE NOT RECRUITING
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Masonic Cancer Center, University of Minnesota
NCT05199051 ACTIVE NOT RECRUITING
A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML
Centre Antoine Lacassagne
NCT05184842 RECRUITING
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Montefiore Medical Center
NCT03404193 ACTIVE NOT RECRUITING
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT07304232 RECRUITING
Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML
Institute of Hematology & Blood Diseases Hospital, China
NCT02782546 ACTIVE NOT RECRUITING
Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
Washington University School of Medicine
NCT04269213 ACTIVE NOT RECRUITING
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
Roswell Park Cancer Institute
NCT05761171 ACTIVE NOT RECRUITING
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
Children's Oncology Group
NCT04802161 ACTIVE NOT RECRUITING
Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes
National Cancer Institute (NCI)
NCT03128034 RECRUITING
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Fred Hutchinson Cancer Center
NCT04068597 RECRUITING
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
NCT03622788 ACTIVE NOT RECRUITING
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
M.D. Anderson Cancer Center
NCT03934372 RECRUITING
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Biosciences International Sàrl
NCT04128748 RECRUITING
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04047641 RECRUITING
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT03247088 ACTIVE NOT RECRUITING
Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
NCT07153068 RECRUITING
SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Institute of Hematology & Blood Diseases Hospital, China
NCT05322850 RECRUITING
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
University of Florida
NCT06680752 RECRUITING
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
ARCE Therapeutics, Inc.
NCT03591510 ACTIVE NOT RECRUITING
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
Novartis Pharmaceuticals
NCT04657081 ACTIVE NOT RECRUITING
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
Taiho Oncology, Inc.
NCT02275533 ACTIVE NOT RECRUITING
Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial
National Cancer Institute (NCI)
NCT04140487 RECRUITING
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
NCT06824168 RECRUITING
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Daiichi Sankyo
NCT03330821 ACTIVE NOT RECRUITING
Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
University of Southern California
NCT03300492 RECRUITING
Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS
University Hospital, Basel, Switzerland
NCT07256210 RECRUITING
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
NCT06973668 RECRUITING
A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease
M.D. Anderson Cancer Center
NCT04493164 RECRUITING
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT03589729 RECRUITING
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
M.D. Anderson Cancer Center
NCT04188405 ACTIVE NOT RECRUITING
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
NCT07238712 RECRUITING
Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor
St. Petersburg State Pavlov Medical University
NCT06532552 RECRUITING
Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
NCT07232953 ACTIVE NOT RECRUITING
Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
NCT06451861 RECRUITING
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
Guangdong Provincial People's Hospital
NCT04060277 ACTIVE NOT RECRUITING
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
City of Hope Medical Center
NCT04801797 RECRUITING
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
Massachusetts General Hospital
NCT07026942 NOT YET RECRUITING
Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML
Nationwide Children's Hospital
NCT04067336 RECRUITING
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
NCT03747757 ACTIVE NOT RECRUITING
Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue
M.D. Anderson Cancer Center
NCT04817241 ACTIVE NOT RECRUITING
Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients
National Cancer Institute (NCI)
NCT04774393 RECRUITING
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT06928662 RECRUITING
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Fred Hutchinson Cancer Center
NCT04093570 ENROLLING BY INVITATION
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Taiho Oncology, Inc.
NCT06128070 RECRUITING
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
City of Hope Medical Center
NCT02756962 ACTIVE NOT RECRUITING
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
Washington University School of Medicine
NCT05285813 ACTIVE NOT RECRUITING
A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure
M.D. Anderson Cancer Center
NCT04975919 ACTIVE NOT RECRUITING
Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT06811233 RECRUITING
Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
M.D. Anderson Cancer Center
NCT05360160 RECRUITING
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
M.D. Anderson Cancer Center
NCT03670966 RECRUITING
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
NCT04231851 ACTIVE NOT RECRUITING
CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
University of California, Irvine
NCT04797767 RECRUITING
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
University of Washington
NCT06529731 RECRUITING
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
Sawa Ito, MD
NCT03586609 RECRUITING
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT04128501 RECRUITING
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
M.D. Anderson Cancer Center
NCT02392572 RECRUITING
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT07214064 NOT YET RECRUITING
Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation
University Hospital Tuebingen
NCT05796570 RECRUITING
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
Franziska Wachter
NCT05226455 RECRUITING
Venetoclax in Patients With MDS or AML in Relapse After AHSCT
Groupe Francophone des Myelodysplasies
NCT06548230 RECRUITING
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
M.D. Anderson Cancer Center
NCT03471260 RECRUITING
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
M.D. Anderson Cancer Center
NCT05211570 RECRUITING
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
AB Science
NCT06930352 NOT YET RECRUITING
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Uma Borate
NCT06561880 RECRUITING
The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation
Institute of Hematology & Blood Diseases Hospital, China
NCT04282187 RECRUITING
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
NCT06668558 RECRUITING
Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
NCT06281847 NOT YET RECRUITING
An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia
Advesya SAS
NCT06704152 RECRUITING
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
BlueSphere Bio, Inc
NCT02392429 ACTIVE NOT RECRUITING
FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT06599762 RECRUITING
Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
University of Manitoba
NCT03970096 RECRUITING
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Fred Hutchinson Cancer Center
NCT05305859 RECRUITING
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
The First Affiliated Hospital of Xiamen University
NCT03953898 ACTIVE NOT RECRUITING
Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation
National Cancer Institute (NCI)
NCT06859424 RECRUITING
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Center for International Blood and Marrow Transplant Research
NCT03214562 RECRUITING
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT03683433 RECRUITING
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
M.D. Anderson Cancer Center
NCT05884333 RECRUITING
Cord Blood Transplant in Adults With Blood Cancers
Memorial Sloan Kettering Cancer Center
NCT04385290 RECRUITING
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
Technische Universität Dresden
NCT04872595 ACTIVE NOT RECRUITING
A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant
Memorial Sloan Kettering Cancer Center
NCT06429098 RECRUITING
Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML
The First Affiliated Hospital of Soochow University
NCT07025824 NOT YET RECRUITING
Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation
Technische Universität Dresden
NCT06504459 RECRUITING
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
OHSU Knight Cancer Institute
NCT03850574 RECRUITING
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Aptose Biosciences Inc.
NCT06129734 RECRUITING
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
Benjamin Tomlinson
NCT02506933 ACTIVE NOT RECRUITING
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT04278768 RECRUITING
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Curis, Inc.
NCT04086264 ACTIVE NOT RECRUITING
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
AbbVie
NCT02790515 ACTIVE NOT RECRUITING
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
St. Jude Children's Research Hospital
NCT07023588 RECRUITING
Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease
Yehui Tan
NCT07108530 RECRUITING
Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study
Shanxi Bethune Hospital
NCT03793478 ACTIVE NOT RECRUITING
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
Daiichi Sankyo
NCT06903702 RECRUITING
A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
NCT06262438 RECRUITING
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
Princess Maxima Center for Pediatric Oncology
NCT04904588 ACTIVE NOT RECRUITING
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
NCT07078591 RECRUITING
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
Beijing 302 Hospital
NCT05735717 RECRUITING
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT07084584 NOT YET RECRUITING
An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Galecto Biotech AB
NCT07069933 NOT YET RECRUITING
Repurposing Itraconazole as an Adjuvant Therapy in Treatment of Patients With Acute Myeloid Leukemia: Is it a Hopeful Avenue for Enhancing Treatment Options?
Mansoura University
NCT04668885 ACTIVE NOT RECRUITING
CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS
Case Comprehensive Cancer Center
NCT03971799 ACTIVE NOT RECRUITING
Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia
Center for International Blood and Marrow Transplant Research
NCT03286530 ACTIVE NOT RECRUITING
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
Massachusetts General Hospital
NCT07060001 NOT YET RECRUITING
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
The Methodist Hospital Research Institute
NCT04195945 ACTIVE NOT RECRUITING
CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients
Fred Hutchinson Cancer Center
NCT07008638 RECRUITING
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
Masonic Cancer Center, University of Minnesota
NCT07028086 RECRUITING
VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma
Ruijin Hospital
NCT03739502 RECRUITING
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
University of Rochester
NCT06717958 RECRUITING
Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation
Technische Universität Dresden
NCT05805605 RECRUITING
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT06199557 RECRUITING
A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients
Haukeland University Hospital
NCT06492304 RECRUITING
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
CRISPR Therapeutics
NCT06815003 RECRUITING
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
City of Hope Medical Center
NCT06802315 RECRUITING
Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
University of Illinois at Chicago
NCT05780879 RECRUITING
A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia
University of Michigan Rogel Cancer Center
NCT03314974 RECRUITING
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
NCT07028073 RECRUITING
A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
NCT06557421 RECRUITING
De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients
Institut Paoli-Calmettes
NCT03836209 ACTIVE NOT RECRUITING
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
PrECOG, LLC.
NCT03597321 ACTIVE NOT RECRUITING
Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML
Institut Paoli-Calmettes
NCT06055621 RECRUITING
Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE
Institut Paoli-Calmettes
NCT05800210 RECRUITING
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
University of Florida
NCT07007949 RECRUITING
a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
NCT04415008 ACTIVE NOT RECRUITING
Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
NCT05364762 ACTIVE NOT RECRUITING
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
City of Hope Medical Center
NCT03031262 ACTIVE NOT RECRUITING
Efficacy and Safety of Chidamide in CBF Leukemia
Institute of Hematology & Blood Diseases Hospital, China
NCT03031249 ENROLLING BY INVITATION
Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
NCT06744556 RECRUITING
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
Institute of Hematology & Blood Diseases Hospital, China
NCT06696183 RECRUITING
Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment
Technische Universität Dresden
NCT06869265 RECRUITING
Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia
Peking University People's Hospital
NCT04730258 ACTIVE NOT RECRUITING
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
Treadwell Therapeutics, Inc
NCT03503409 ACTIVE NOT RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
Groupe Francophone des Myelodysplasies
NCT04482894 ACTIVE NOT RECRUITING
Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS
University of Virginia
NCT05401097 RECRUITING
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Alice Mims
NCT06268574 ACTIVE NOT RECRUITING
Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML
Ryvu Therapeutics SA
NCT03573024 ACTIVE NOT RECRUITING
Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia
University of Colorado, Denver
NCT04836390 ENROLLING BY INVITATION
Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant
Michael Pulsipher
NCT02646839 ENROLLING BY INVITATION
KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children
Michael Pulsipher
NCT04050280 RECRUITING
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
University of Maryland, Baltimore
NCT04232241 ACTIVE NOT RECRUITING
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia
Universitätsklinikum Hamburg-Eppendorf
NCT06928376 RECRUITING
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
Chinese PLA General Hospital
NCT06355583 RECRUITING
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial
Imperial College London
NCT06191263 RECRUITING
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
Ryvu Therapeutics SA
NCT05133882 RECRUITING
A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
Sunshine Lake Pharma Co., Ltd.
NCT04742101 ACTIVE NOT RECRUITING
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia
Institut de Recherches Internationales Servier
NCT05241093 RECRUITING
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Tarapeutics Science Inc.
NCT06156579 RECRUITING
Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML
University Hospital Tuebingen
NCT06911710 RECRUITING
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
Tianjin Medical University General Hospital
NCT06900088 NOT YET RECRUITING
Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
Institute of Hematology & Blood Diseases Hospital, China
NCT06839456 RECRUITING
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Children's Hospital of Philadelphia
NCT06022003 RECRUITING
Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
French Innovative Leukemia Organisation
NCT06561152 RECRUITING
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
Stanford University
NCT05583552 ACTIVE NOT RECRUITING
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
GCP-Service International West GmbH
NCT06667973 NOT YET RECRUITING
Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT06059391 RECRUITING
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT02781883 RECRUITING
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Bio-Path Holdings, Inc.
NCT04049539 RECRUITING
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
Ohio State University Comprehensive Cancer Center
NCT03728335 RECRUITING
Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation
City of Hope Medical Center
NCT04980885 ACTIVE NOT RECRUITING
A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia
Akeso
NCT06299462 RECRUITING
PTCy and ATG for MSD and MUD Transplants
Instituto Nacional de Cancer, Brazil
NCT05029141 ACTIVE NOT RECRUITING
New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
NCT06827899 RECRUITING
Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML
The First Affiliated Hospital of Xiamen University
NCT05603884 RECRUITING
VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
The First Affiliated Hospital of Xiamen University
NCT06816134 RECRUITING
Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
The First Affiliated Hospital of Soochow University
NCT06220162 RECRUITING
VAC Regimen for AML Patients Who Failed to Response to VA Regimen
The First Affiliated Hospital of Soochow University
NCT05601726 RECRUITING
First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
Advanced BioDesign
NCT06783790 RECRUITING
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT
Institute of Hematology & Blood Diseases Hospital, China
NCT06783478 NOT YET RECRUITING
NK Cell Infusion for Remission Consolidation in AML: A Phase II Trial
Hospital de Clinicas de Porto Alegre
NCT06754540 NOT YET RECRUITING
Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT03466294 ACTIVE NOT RECRUITING
Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML
University of Colorado, Denver
NCT06765928 NOT YET RECRUITING
Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT
Ruijin Hospital
NCT04476199 ACTIVE NOT RECRUITING
Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT
Gruppo Italiano Trapianto di Midollo Osseo
NCT06379360 RECRUITING
Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients
The First Affiliated Hospital of Soochow University
NCT06741722 RECRUITING
Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML
Beijing 302 Hospital
NCT06746519 RECRUITING
BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia
Chen Suning
NCT05833438 RECRUITING
Venetoclax in Combination with 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy
University of Leipzig
NCT05904106 RECRUITING
Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML
Technische Universität Dresden
NCT06420063 RECRUITING
Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
Essen Biotech
NCT04763928 ACTIVE NOT RECRUITING
Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax
Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT06024031 ACTIVE NOT RECRUITING
NAC for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After Chemotherapy
Peking University People's Hospital
NCT05503134 RECRUITING
Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML
Nationwide Children's Hospital
NCT03609060 ACTIVE NOT RECRUITING
Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML)
French Innovative Leukemia Organisation
NCT03603795 ACTIVE NOT RECRUITING
Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy
French Innovative Leukemia Organisation
NCT06652685 NOT YET RECRUITING
Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Ruijin Hospital
NCT06635681 RECRUITING
Efficacy of Venetoclax Combined with Intensive Chemotherapy in Different Subgroups of AML
Institute of Hematology & Blood Diseases Hospital, China
NCT06621199 RECRUITING
Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML
First Affiliated Hospital of Zhejiang University
NCT06598384 NOT YET RECRUITING
VA as Maintenance Therapy Post Allo-HSCT in MDS and AML
Navy General Hospital, Beijing
NCT06602323 NOT YET RECRUITING
TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
NCT04097470 ACTIVE NOT RECRUITING
Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients
Stichting Hemato-Oncologie voor Volwassenen Nederland
NCT05272293 RECRUITING
Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
NCT05334693 RECRUITING
Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
NCT06470841 NOT YET RECRUITING
CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML
Navy General Hospital, Beijing
NCT06316960 RECRUITING
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
Children's Hospital of Soochow University
NCT06221683 RECRUITING
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
Children's Hospital of Soochow University
NCT06536959 RECRUITING
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
Beijing 302 Hospital
NCT06537843 RECRUITING
Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia
Hospital Municipal São José
NCT06532084 RECRUITING
Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen
St. Petersburg State Pavlov Medical University
NCT06532058 RECRUITING
Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia
Changzhou Qianhong Bio-pharma Co., Ltd.
NCT06508099 RECRUITING
Vitamin A and D Supplementation in Allogeneic HCT
St. Petersburg State Pavlov Medical University
NCT06497062 NOT YET RECRUITING
Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Shanghai Jiao Tong University School of Medicine
NCT06477549 RECRUITING
BeFluBu vs FluBuRux Conditioning in Haploidentical HCT
St. Petersburg State Pavlov Medical University
NCT04968015 ACTIVE NOT RECRUITING
Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission
French Innovative Leukemia Organisation
NCT06447090 RECRUITING
VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT
Institute of Hematology & Blood Diseases Hospital, China
NCT03192397 ACTIVE NOT RECRUITING
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
NCT05580861 RECRUITING
Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment
Assistance Publique - Hôpitaux de Paris
NCT04905810 RECRUITING
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
Brian Jonas
NCT05241106 RECRUITING
A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Tarapeutics Science Inc.
NCT05807932 RECRUITING
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Heinrich-Heine University, Duesseldorf
NCT06394011 RECRUITING
Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients
The First Affiliated Hospital of Soochow University
NCT06387420 NOT YET RECRUITING
A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia
Akeso
NCT04347616 RECRUITING
Natural Killer-cell Therapy for Acute Myeloid Leukemia
Radboud University Medical Center
NCT06206174 RECRUITING
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Shenzhen TargetRx, Inc.
NCT03455504 ACTIVE NOT RECRUITING
Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT05319249 NOT YET RECRUITING
Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia
German Cancer Research Center
NCT06050941 NOT YET RECRUITING
Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS
First Affiliated Hospital of Zhejiang University
NCT06046313 RECRUITING
Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS
First Affiliated Hospital of Zhejiang University
NCT03374332 ACTIVE NOT RECRUITING
Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia
Brown University
NCT05260528 RECRUITING
CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
Centre Hospitalier Universitaire de Nice
NCT06014489 RECRUITING
A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML
Stichting Hemato-Oncologie voor Volwassenen Nederland
NCT05788679 RECRUITING
A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS
Karolinska University Hospital
NCT06133556 NOT YET RECRUITING
Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML
Institute of Hematology & Blood Diseases Hospital, China
NCT06125652 RECRUITING
Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
Xuzhou Medical University
NCT04061239 RECRUITING
Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML
GWT-TUD GmbH
NCT03825796 ACTIVE NOT RECRUITING
CPX-351 Plus Enasidenib for Relapsed AML
Jonsson Comprehensive Cancer Center
NCT06006403 RECRUITING
Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
Chongqing Precision Biotech Co., Ltd
NCT05858814 RECRUITING
RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT
Guangdong Ruishun Biotech Co., Ltd
NCT05736978 RECRUITING
Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
Shanghai Tong Ren Hospital
NCT05736965 RECRUITING
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia
Shanghai Tong Ren Hospital
NCT04913922 RECRUITING
Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML
Ludwig-Maximilians - University of Munich
NCT05584761 RECRUITING
Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML
The First Affiliated Hospital with Nanjing Medical University
NCT03852407 RECRUITING
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
University of Liege
NCT05522192 RECRUITING
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
Hui Zeng
NCT05445154 RECRUITING
SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NCT05431257 RECRUITING
Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
Rigshospitalet, Denmark
NCT05055791 NOT YET RECRUITING
A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NCT05025098 RECRUITING
Precision Therapy Versus Standard Therapy in AML and MDS in Elderly
University Hospital, Akershus
NCT02286726 COMPLETED
CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT04620681 COMPLETED
CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML
H. Lee Moffitt Cancer Center and Research Institute
NCT05906914 COMPLETED
Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia
First Affiliated Hospital of Zhejiang University
NCT06068621 COMPLETED
Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia
Chinese PLA General Hospital
NCT04150029 TERMINATED
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
Novartis Pharmaceuticals
NCT05799079 TERMINATED
Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant
Sanjay Mohan
NCT04240002 TERMINATED
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Astellas Pharma Global Development, Inc.
NCT03055286 TERMINATED
Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
JW Pharmaceutical
NCT05115630 COMPLETED
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
M.D. Anderson Cancer Center
NCT04191187 COMPLETED
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
NCT05955261 SUSPENDED
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
St. Jude Children's Research Hospital
NCT05361057 TERMINATED
Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients
Institute of Hematology & Blood Diseases Hospital, China
NCT02684162 COMPLETED
Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant
M.D. Anderson Cancer Center
NCT03226418 COMPLETED
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
University of Nebraska
NCT04874194 TERMINATED
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
M.D. Anderson Cancer Center
NCT04511130 TERMINATED
Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
Marker Therapeutics, Inc.
NCT04266795 COMPLETED
A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy
Takeda
NCT04848974 COMPLETED
Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT04623216 TERMINATED
Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.
Novartis Pharmaceuticals
NCT03118466 COMPLETED
Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
Massachusetts General Hospital
NCT03068819 COMPLETED
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant
Washington University School of Medicine
NCT06563804 TERMINATED
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Servier Bio-Innovation LLC
NCT05358808 TERMINATED
ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)
TC Biopharm
NCT03878199 COMPLETED
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Ohio State University Comprehensive Cancer Center
NCT03860844 TERMINATED
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Sanofi
NCT02438761 TERMINATED
PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)
Institut Curie
NCT04107727 COMPLETED
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
PETHEMA Foundation
NCT02310321 COMPLETED
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
Astellas Pharma Inc
NCT06679582 TERMINATED
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
Sutro Biopharma, Inc.
NCT06508489 TERMINATED
A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies
Sanofi
NCT02793544 COMPLETED
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
NCT05662956 COMPLETED
A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients
Hematology department of the 920th hospital
NCT02722668 COMPLETED
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
NCT03333486 TERMINATED
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
NCT04669210 COMPLETED
PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT
St. Petersburg State Pavlov Medical University
NCT02719574 COMPLETED
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
Forma Therapeutics, Inc.
NCT05024994 COMPLETED
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers
Memorial Sloan Kettering Cancer Center
NCT03724084 TERMINATED
Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement
National Cancer Institute (NCI)
NCT02257138 COMPLETED
Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT02397720 COMPLETED
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT02220985 COMPLETED
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Fred Hutchinson Cancer Center
NCT03246906 TERMINATED
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
NCT03844997 COMPLETED
Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia
Sudipto Mukherjee, MD, PhD, MPH
NCT02937662 COMPLETED
Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML
Institute of Hematology & Blood Diseases Hospital, China
NCT06449482 TERMINATED
Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy
Institute of Hematology & Blood Diseases Hospital, China
NCT03021395 WITHDRAWN
Efficacy of Decitabine in Clearance of MRD
Institute of Hematology & Blood Diseases Hospital, China
NCT04752163 TERMINATED
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT03537599 TERMINATED
Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant
Sumithira Vasu
NCT04827719 COMPLETED
BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS
Groupe Francophone des Myelodysplasies
NCT05447663 TERMINATED
A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant
Novartis Pharmaceuticals
NCT04857645 COMPLETED
ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients
Groupe Francophone des Myelodysplasies
NCT04435691 TERMINATED
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT02566304 COMPLETED
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03434730 COMPLETED
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Memorial Sloan Kettering Cancer Center
NCT04487106 COMPLETED
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT05766514 WITHDRAWN
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
University of Florida
NCT02658487 COMPLETED
Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia
Vanderbilt-Ingram Cancer Center
NCT03615105 TERMINATED
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Memorial Sloan Kettering Cancer Center
NCT03150004 TERMINATED
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Medical College of Wisconsin
NCT03280030 COMPLETED
A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML
Novartis Pharmaceuticals
NCT02649790 COMPLETED
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
Karyopharm Therapeutics Inc
NCT06113289 WITHDRAWN
A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT06865352 COMPLETED
Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation
Fondazione IRCCS Policlinico San Matteo di Pavia
NCT02396134 COMPLETED
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT03686345 TERMINATED
Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia
Niguarda Hospital
NCT04905407 TERMINATED
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Syros Pharmaceuticals
NCT06150040 TERMINATED
Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]
Centre Leon Berard
NCT03839446 COMPLETED
Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy
Robert Redner, MD
NCT04342962 TERMINATED
Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT04914676 TERMINATED
Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission
University of Florida
NCT04083170 TERMINATED
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Fred Hutchinson Cancer Center
NCT04029688 TERMINATED
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Hoffmann-La Roche
NCT02807558 COMPLETED
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Syros Pharmaceuticals
NCT04582864 TERMINATED
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
Washington University School of Medicine
NCT03730012 COMPLETED
A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)
Astellas Pharma Global Development, Inc.
NCT02927262 COMPLETED
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Astellas Pharma Global Development, Inc.
NCT04079296 COMPLETED
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
Astellas Pharma Global Development, Inc.
NCT03761914 COMPLETED
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Sellas Life Sciences Group
NCT02561455 COMPLETED
Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial
Astellas Pharma Global Development, Inc.
NCT05659992 COMPLETED
Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Chinese PLA General Hospital
NCT04762875 TERMINATED
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
Ensoma
NCT04992949 COMPLETED
Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm
French Innovative Leukemia Organisation
NCT02532231 COMPLETED
Nivolumab in AML in Remission at High Risk for Relapse
M.D. Anderson Cancer Center
NCT04151706 COMPLETED
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
Robert Lowsky
NCT02270463 TERMINATED
SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
Stemline Therapeutics, Inc.
NCT03941769 COMPLETED
2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II
M.D. Anderson Cancer Center
NCT04982354 WITHDRAWN
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
Guenther Koehne
NCT02768792 COMPLETED
High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML
UNC Lineberger Comprehensive Cancer Center
NCT03735875 TERMINATED
Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT06586099 WITHDRAWN
Tislelizumab with Azacitidine in the Treatment of R/R AML
Institute of Hematology & Blood Diseases Hospital, China
NCT03922100 TERMINATED
Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML
Nerviano Medical Sciences
NCT05682170 TERMINATED
Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
NCT05854966 WITHDRAWN
CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Wake Forest University Health Sciences
NCT03154827 TERMINATED
Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)
BioLineRx, Ltd.
NCT04267081 COMPLETED
Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening
Helsinki University Central Hospital
NCT05028751 TERMINATED
A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
Kronos Bio
NCT03902665 COMPLETED
Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT02626715 COMPLETED
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
Randy Windreich
NCT03088709 TERMINATED
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Loyola University
NCT02400281 COMPLETED
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Arog Pharmaceuticals, Inc.
NCT04969601 COMPLETED
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
Assistance Publique - Hôpitaux de Paris
NCT04835519 COMPLETED
Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Beijing Boren Hospital
NCT06337331 WITHDRAWN
Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant
Northside Hospital, Inc.
NCT03493646 COMPLETED
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486
Kirby Institute
NCT04526288 TERMINATED
CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease
Fred Hutchinson Cancer Center
NCT03678493 COMPLETED
A Study of FMT in Patients With AML Allo HSCT in Recipients
Masonic Cancer Center, University of Minnesota
NCT03047993 COMPLETED
Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT02942758 TERMINATED
Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML
University Hospital Regensburg
NCT05895201 WITHDRAWN
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Indiana University
NCT05433532 COMPLETED
Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
The First Affiliated Hospital of Soochow University
NCT04202003 COMPLETED
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
TJ Biopharma Co., Ltd.
NCT05367401 WITHDRAWN
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Novartis Pharmaceuticals
NCT02340884 COMPLETED
A Pilot RCT of the PRISM Intervention for AYAs With Cancer
Seattle Children's Hospital
NCT02446145 TERMINATED
A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients
Technische Universität Dresden
NCT04113616 TERMINATED
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
Kartos Therapeutics, Inc.
NCT05345938 TERMINATED
A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NCT02508324 TERMINATED
IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia
Weill Medical College of Cornell University
NCT05829434 WITHDRAWN
Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS
Uwe Platzbecker
NCT04956042 TERMINATED
Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia
CicloMed LLC
NCT02283177 COMPLETED
A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
Arog Pharmaceuticals, Inc.
NCT04092179 TERMINATED
Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
University Health Network, Toronto
NCT03128359 COMPLETED
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
City of Hope Medical Center
NCT05066165 TERMINATED
Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia
Intellia Therapeutics
NCT06180863 WITHDRAWN
Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients
Yale University
NCT02626338 COMPLETED
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Arog Pharmaceuticals, Inc.
NCT02400255 COMPLETED
Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients
Arog Pharmaceuticals, Inc.
NCT03734601 COMPLETED
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Stanford University
NCT05201183 WITHDRAWN
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Naoyuki G. Saito, M.D., Ph.D.
NCT02509546 COMPLETED
8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
NCT03969420 TERMINATED
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
Sumitomo Pharma America, Inc.
NCT04055844 COMPLETED
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
Masonic Cancer Center, University of Minnesota
NCT02639559 COMPLETED
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Washington University School of Medicine
NCT02989844 COMPLETED
Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT
Masonic Cancer Center, University of Minnesota
NCT04485052 SUSPENDED
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia
Innovent Biologics (Suzhou) Co. Ltd.
NCT03701295 COMPLETED
Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement
National Cancer Institute (NCI)
NCT03096782 COMPLETED
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
M.D. Anderson Cancer Center
NCT02583893 COMPLETED
Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT02743611 TERMINATED
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
Bellicum Pharmaceuticals
NCT04166929 TERMINATED
Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT02073838 COMPLETED
Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML
Sarit Assouline
NCT02771197 COMPLETED
Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
Northside Hospital, Inc.
NCT02661035 COMPLETED
Allo HSCT Using RIC for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT03067571 TERMINATED
Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04002115 TERMINATED
Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML
Milton S. Hershey Medical Center
NCT04079738 TERMINATED
Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib
H Scott Boswell
NCT02642965 COMPLETED
Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Children's Oncology Group
NCT02873338 COMPLETED
Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
Jazz Pharmaceuticals
NCT03390296 COMPLETED
OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT05320380 WITHDRAWN
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
Children's Oncology Group
NCT03531918 COMPLETED
Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm
Fred Hutchinson Cancer Center
NCT04712942 COMPLETED
Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat
University of Leipzig
NCT03267186 COMPLETED
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
Andrew Rezvani
NCT03435848 COMPLETED
Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy
BioSight Ltd.
NCT03932318 WITHDRAWN
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
Actinium Pharmaceuticals
NCT03050216 COMPLETED
QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML
Masonic Cancer Center, University of Minnesota
NCT02842827 COMPLETED
A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
NCT02728050 COMPLETED
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
University of Washington
NCT04562792 COMPLETED
Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia
Children's Mercy Hospital Kansas City
NCT03745352 WITHDRAWN
Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT03634228 TERMINATED
Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT01806571 COMPLETED
Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Mayo Clinic
NCT03417154 COMPLETED
Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS
Masonic Cancer Center, University of Minnesota
NCT04146038 COMPLETED
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
Rutgers, The State University of New Jersey
NCT02581007 COMPLETED
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Northside Hospital, Inc.
NCT04354025 WITHDRAWN
Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML
Washington University School of Medicine
NCT02878785 COMPLETED
Decitabine and Talazoparib in Untreated AML and R/R AML
University of Maryland, Baltimore
NCT04173585 COMPLETED
TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib
University Hospital Heidelberg
NCT02845297 COMPLETED
Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03303339 COMPLETED
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)
Cardiff Oncology
NCT02323113 TERMINATED
Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
Calithera Biosciences, Inc
NCT02743351 COMPLETED
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Fate Therapeutics
NCT05048615 COMPLETED
Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML
Hospital Universitario Dr. Jose E. Gonzalez
NCT02593123 COMPLETED
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Virginia Commonwealth University
NCT02996474 COMPLETED
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
National Heart, Lung, and Blood Institute (NHLBI)
NCT02539459 TERMINATED
Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus
Fox Chase Cancer Center
NCT03214666 TERMINATED
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
GT Biopharma, Inc.
NCT05246384 WITHDRAWN
Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
Rhizen Pharmaceuticals SA
NCT04424147 COMPLETED
Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML
Nanfang Hospital, Southern Medical University
NCT02686593 COMPLETED
Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML
The University of Hong Kong
NCT04282174 WITHDRAWN
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
Baptist Health South Florida
NCT04425655 TERMINATED
Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.
University of California, San Diego
NCT04230239 COMPLETED
Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia
PETHEMA Foundation
NCT03455140 COMPLETED
A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)
University of Birmingham
NCT03760666 TERMINATED
A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Clear Creek Bio, Inc.
NCT02773732 TERMINATED
Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101)
University of Florida
NCT03850535 TERMINATED
A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Hoffmann-La Roche
NCT05279859 WITHDRAWN
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies
Erasca, Inc.
NCT03063203 TERMINATED
Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
Washington University School of Medicine
NCT03600909 TERMINATED
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
Memorial Sloan Kettering Cancer Center
NCT02665143 COMPLETED
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
Yale University
NCT03985007 COMPLETED
CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
NCT04893915 WITHDRAWN
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Washington University School of Medicine
NCT03012672 COMPLETED
Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm
University of Washington
NCT03072043 COMPLETED
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
H. Lee Moffitt Cancer Center and Research Institute
NCT03951961 TERMINATED
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
University of Jena
NCT04044209 WITHDRAWN
A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
Yale University
NCT04097301 TERMINATED
Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma
AGC Biologics S.p.A.
NCT05063123 WITHDRAWN
Study to Assess an Interphase Cycle With Flotetuzumab.
Stichting Hemato-Oncologie voor Volwassenen Nederland
NCT03824080 COMPLETED
Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes
GWT-TUD GmbH
NCT05149339 COMPLETED
Vitamin D Effect on A Disintegrin-like And Metalloprotease Thrombospondin1 Motif 13& Interleukin 6 in Leukemia
Zagazig University
NCT03557970 TERMINATED
JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia
OHSU Knight Cancer Institute
NCT02795520 TERMINATED
Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia
OncoTherapy Science, Inc.
NCT02756572 COMPLETED
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
University of Washington
NCT02770820 TERMINATED
Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
NCT03019939 COMPLETED
Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia
M.D. Anderson Cancer Center
NCT04051996 TERMINATED
GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia
Yale University
NCT02464657 COMPLETED
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
NCT02328755 COMPLETED
Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia
University of Michigan Rogel Cancer Center
NCT02229266 TERMINATED
Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML
Technische Universität Dresden
NCT03397173 COMPLETED
TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid
Case Comprehensive Cancer Center
NCT02708641 COMPLETED
A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML
Michael Boyiadzis
NCT02440568 TERMINATED
AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients
University of Illinois at Chicago
NCT03451084 COMPLETED
A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia
ASLAN Pharmaceuticals
NCT03602898 WITHDRAWN
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
Fred Hutchinson Cancer Center
NCT02424968 COMPLETED
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Robert Lowsky
NCT04395092 WITHDRAWN
Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
Kiadis Pharma
NCT02500550 COMPLETED
Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
Kiadis Pharma
NCT03466320 COMPLETED
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2
Celyad Oncology SA
NCT02648932 TERMINATED
The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients
University of Chicago
NCT03113071 TERMINATED
Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
Fox Chase Cancer Center
NCT03881735 WITHDRAWN
Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation
Roswell Park Cancer Institute
NCT03515707 WITHDRAWN
Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
NCT03709576 TERMINATED
Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML
Milton S. Hershey Medical Center
NCT02799147 COMPLETED
GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
St. Petersburg State Pavlov Medical University
NCT04493099 WITHDRAWN
Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML
M.D. Anderson Cancer Center
NCT03338348 COMPLETED
Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
University of Ulm
NCT02953561 TERMINATED
Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT02458235 COMPLETED
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
University of California, San Francisco
NCT02763475 COMPLETED
NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents
Instituto de Investigación Hospital Universitario La Paz
NCT02991898 TERMINATED
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT03059615 WITHDRAWN
A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS
Immune System Key Ltd
NCT04013880 WITHDRAWN
ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
Vanderbilt-Ingram Cancer Center
NCT03718143 TERMINATED
AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis
NYU Langone Health
NCT02923986 WITHDRAWN
Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
Bio-Path Holdings, Inc.
NCT03071276 TERMINATED
Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
NCT02560025 COMPLETED
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
Massachusetts General Hospital
NCT02530476 COMPLETED
Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT04100330 WITHDRAWN
A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia
AVEO Pharmaceuticals, Inc.
NCT03170895 COMPLETED
Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD
The University of Hong Kong
NCT02921061 COMPLETED
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
Fred Hutchinson Cancer Center
NCT02416908 COMPLETED
Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
Washington University School of Medicine
NCT02343939 TERMINATED
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
Gilead Sciences
NCT03195010 TERMINATED
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Fred Hutchinson Cancer Center
NCT02399917 TERMINATED
Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT02666950 COMPLETED
WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Mayo Clinic
NCT02337478 TERMINATED
Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Wake Forest University Health Sciences
NCT02634827 TERMINATED
Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation
Mayo Clinic
NCT02477787 TERMINATED
Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS
Asan Medical Center
NCT02662647 COMPLETED
Decitabine Based Chemotherapy Followed by Haploidentical Lymphocyte Infusion for Elderly Patients With AML
Chinese PLA General Hospital
NCT03146871 TERMINATED
Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent
University of Southern California
NCT03381118 TERMINATED
Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients
St. Petersburg State Pavlov Medical University
NCT02418000 TERMINATED
A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations
Spirita Oncology, LLC
NCT03187691 WITHDRAWN
Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia
Matinas BioPharma Nanotechnologies, Inc.
NCT03699384 WITHDRAWN
Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)
Memorial Sloan Kettering Cancer Center
NCT03324243 WITHDRAWN
A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia
Arog Pharmaceuticals, Inc.
NCT02614560 TERMINATED
A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients
Seagen Inc.
NCT03438344 WITHDRAWN
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT02587871 WITHDRAWN
Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission
University of Southern California
NCT03365661 WITHDRAWN
QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML
Masonic Cancer Center, University of Minnesota
NCT02992860 TERMINATED
Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY
GWT-TUD GmbH
NCT03207334 WITHDRAWN
iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)
University of Florida
NCT02732184 COMPLETED
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS
Aeglea Biotherapeutics
NCT02550535 COMPLETED
A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients
Cell Medica Ltd
NCT02351037 TERMINATED
Study of Ibrutinib in Subjects With Acute Myeloid Leukemia
Pharmacyclics LLC.
NCT02472626 WITHDRAWN
6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Wake Forest University Health Sciences
NCT02532010 TERMINATED
Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML
Weill Medical College of Cornell University
NCT02462265 SUSPENDED
Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients
Oshadi Drug Administration
NCT02204020 WITHDRAWN
Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS
University of Pittsburgh
NCT02269579 WITHDRAWN
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
Jazz Pharmaceuticals
NCT02419755 TERMINATED
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
St. Jude Children's Research Hospital
NCT02198482 TERMINATED
Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
University of Ulm
NCT02395822 COMPLETED
MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients
Masonic Cancer Center, University of Minnesota
NCT02856178 WITHDRAWN
Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients
F2G Biotech GmbH
NCT03036046 WITHDRAWN
Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml Leukaemia
F2G Biotech GmbH
NCT02765997 WITHDRAWN
StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT03108911 TERMINATED
Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy
Rutgers, The State University of New Jersey
NCT02433483 TERMINATED
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
St. Jude Children's Research Hospital
NCT02544438 COMPLETED
Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
BioSight Ltd.
NCT02829840 WITHDRAWN
Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
NCT02520102 WITHDRAWN
Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia
Sanofi
NCT01520805 WITHDRAWN
Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome
Cornerstone Pharmaceuticals
NCT02303782 WITHDRAWN
A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT01010373 SUSPENDED
Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients
BioMAS Ltd
NCT07384715 RECRUITING
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
Genmab
NCT04190550 ACTIVE NOT RECRUITING
Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT07012044 NOT YET RECRUITING
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT06484062 RECRUITING
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
National Cancer Institute (NCI)
NCT03041688 ACTIVE NOT RECRUITING
Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT05886049 RECRUITING
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene
National Cancer Institute (NCI)
NCT03983824 ACTIVE NOT RECRUITING
Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT06177067 RECRUITING
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
NCT03844815 ACTIVE NOT RECRUITING
Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia
University of Chicago
NCT03816319 RECRUITING
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
National Cancer Institute (NCI)
NCT07044544 RECRUITING
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
University of Alabama at Birmingham
NCT07283094 RECRUITING
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
Montefiore Medical Center
NCT06846606 ACTIVE NOT RECRUITING
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Auron Therapeutics, Inc.
NCT07439211 NOT YET RECRUITING
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Jacqueline Garcia, MD
NCT06514261 RECRUITING
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
National Cancer Institute (NCI)
NCT03630991 RECRUITING
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
M.D. Anderson Cancer Center
NCT07441980 NOT YET RECRUITING
A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
NCT05558124 RECRUITING
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
H. Lee Moffitt Cancer Center and Research Institute
NCT07432100 NOT YET RECRUITING
Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia
Mingfeng Zhao
NCT06247787 RECRUITING
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
Children's Oncology Group
NCT06445907 RECRUITING
Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT06285890 RECRUITING
Phase I Study of HC-7366 for Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT03802695 RECRUITING
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc.
NCT07177079 NOT YET RECRUITING
High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)
Kittika Poonsombudlert
NCT05918692 ACTIVE NOT RECRUITING
A Phase 1 Study of BMF-500 in Adults With Acute Leukemia
Biomea Fusion Inc.
NCT06034470 RECRUITING
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
Fred Hutchinson Cancer Center
NCT06017258 RECRUITING
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
NCT06616636 RECRUITING
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
M.D. Anderson Cancer Center
NCT06191978 RECRUITING
A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
NCT05627232 RECRUITING
Tazemetostat and Palbociclib With CPX-351for R/R AML
Thomas Jefferson University
NCT06226571 RECRUITING
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
Syndax Pharmaceuticals
NCT07411586 NOT YET RECRUITING
Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT07295951 RECRUITING
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
Janssen Research & Development, LLC
NCT06656494 RECRUITING
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.
NCT06325748 ACTIVE NOT RECRUITING
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
Senti Biosciences
NCT06769490 RECRUITING
Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT05748197 RECRUITING
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
NCT05015426 ACTIVE NOT RECRUITING
Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT
H. Lee Moffitt Cancer Center and Research Institute
NCT06950034 RECRUITING
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Solu Therapeutics, Inc
NCT07130695 RECRUITING
Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation
Virginia Commonwealth University
NCT06372717 RECRUITING
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
Apollo Therapeutics Ltd
NCT04716452 RECRUITING
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Keystone Nano, Inc
NCT06810583 RECRUITING
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
St. Jude Children's Research Hospital
NCT06551584 RECRUITING
Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Stanford University
NCT07011004 RECRUITING
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
Memorial Sloan Kettering Cancer Center
NCT07270978 RECRUITING
Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
University of Virginia
NCT07321626 RECRUITING
Romiplostim N01 for Platelet Recovery After Haploidentical HSCT
First Affiliated Hospital of Zhejiang University
NCT05455294 ACTIVE NOT RECRUITING
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
Jacqueline Garcia, MD
NCT07374029 NOT YET RECRUITING
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
David Avigan
NCT07250646 NOT YET RECRUITING
A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
Aspera Biomedicines, Inc.
NCT06871410 RECRUITING
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Roswell Park Cancer Institute
NCT04898894 ACTIVE NOT RECRUITING
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
NCT04158739 ACTIVE NOT RECRUITING
Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia
Children's Oncology Group
NCT06326463 RECRUITING
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
St. Jude Children's Research Hospital
NCT07355335 NOT YET RECRUITING
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
Massachusetts General Hospital
NCT06197672 RECRUITING
Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant
Huda Salman
NCT03679650 ACTIVE NOT RECRUITING
Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients
Beth Israel Deaconess Medical Center
NCT05001828 ACTIVE NOT RECRUITING
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia
Polaris Group
NCT06359002 ACTIVE NOT RECRUITING
Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.
Byondis B.V.
NCT04953897 RECRUITING
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Taiho Oncology, Inc.
NCT04953910 RECRUITING
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Taiho Oncology, Inc.
NCT06146257 RECRUITING
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
GluBio Therapeutics Inc.
NCT07347171 RECRUITING
A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
Cullgen (Shanghai),Inc
NCT07347418 NOT YET RECRUITING
CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML or HR-MDS
University of Colorado, Denver
NCT06768476 ACTIVE NOT RECRUITING
CART123 + Ruxolitinib in Relapsed/Refractory AML
University of Pennsylvania
NCT03709758 ACTIVE NOT RECRUITING
Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML
Dana-Farber Cancer Institute
NCT05143996 RECRUITING
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Cullinan Therapeutics Inc.
NCT05287568 RECRUITING
CC-486 and Venetoclax for Acute Myeloid Leukemia
University of Colorado, Denver
NCT05010772 RECRUITING
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
M.D. Anderson Cancer Center
NCT05188170 RECRUITING
Niclosamide in Pediatric Patients With Relapsed and Refractory AML
Stanford University
NCT05317403 RECRUITING
Venetoclax to Augment Epigenetic Modification and Chemotherapy
Medical College of Wisconsin
NCT06609928 RECRUITING
FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
NCT05342584 RECRUITING
Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
Montefiore Medical Center
NCT05597306 RECRUITING
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Terrence J Bradley, MD
NCT05263284 RECRUITING
8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
City of Hope Medical Center
NCT04872478 RECRUITING
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
Meryx, Inc.
NCT02530034 ACTIVE NOT RECRUITING
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
NCT03912064 ACTIVE NOT RECRUITING
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Dana-Farber Cancer Institute
NCT06138587 RECRUITING
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Dana-Farber Cancer Institute
NCT04024761 RECRUITING
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Dana-Farber Cancer Institute
NCT06366789 RECRUITING
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia
Lomond Therapeutics Holdings, Inc.
NCT06714591 RECRUITING
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
SystImmune Inc.
NCT05834244 RECRUITING
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
M.D. Anderson Cancer Center
NCT07306832 NOT YET RECRUITING
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
AbbVie
NCT07303660 NOT YET RECRUITING
A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients
Lomond Therapeutics Holdings, Inc.
NCT03613532 ACTIVE NOT RECRUITING
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
Jacqueline Garcia, MD
NCT07302776 NOT YET RECRUITING
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Stanford University
NCT05105152 RECRUITING
PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
Seattle Children's Hospital
NCT04659616 RECRUITING
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
OHSU Knight Cancer Institute
NCT06552416 RECRUITING
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
Marker Therapeutics, Inc.
NCT06448013 RECRUITING
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT03560752 ACTIVE NOT RECRUITING
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
City of Hope Medical Center
NCT04227847 RECRUITING
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
Seagen, a wholly owned subsidiary of Pfizer
NCT05024552 RECRUITING
Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
H. Lee Moffitt Cancer Center and Research Institute
NCT03969446 RECRUITING
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
City of Hope Medical Center
NCT06649227 RECRUITING
Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19
University Hospital, Lille
NCT07263906 RECRUITING
Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT06001788 RECRUITING
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
NCT05534620 RECRUITING
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
medac GmbH
NCT05636514 RECRUITING
Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
Clinical Hub for Interventional Research (CHOIR)
NCT02483312 ACTIVE NOT RECRUITING
A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)
University Health Network, Toronto
NCT07254793 NOT YET RECRUITING
Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
University of Arizona
NCT06812104 RECRUITING
Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Kyowa Kirin Co., Ltd.
NCT07233018 NOT YET RECRUITING
A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/ Refractory Acute Myeloid Leukemia
MEI HENG
NCT03326921 RECRUITING
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT05146739 ACTIVE NOT RECRUITING
Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane
National Cancer Institute (NCI)
NCT03494569 RECRUITING
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
NCT06195891 RECRUITING
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
NCT05986240 RECRUITING
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
Montefiore Medical Center
NCT03113643 RECRUITING
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Dana-Farber Cancer Institute
NCT02390635 ACTIVE NOT RECRUITING
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT03132454 ACTIVE NOT RECRUITING
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia
M.D. Anderson Cancer Center
NCT06549790 RECRUITING
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Nerviano Medical Sciences
NCT06419634 RECRUITING
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Bristol-Myers Squibb
NCT04318678 RECRUITING
CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
St. Jude Children's Research Hospital
NCT06533761 RECRUITING
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Stelexis BioSciences
NCT02494167 ACTIVE NOT RECRUITING
Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)
Baylor College of Medicine
NCT03513484 ACTIVE NOT RECRUITING
Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia
Northwestern University
NCT05744739 ACTIVE NOT RECRUITING
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
Northwestern University
NCT05396859 ACTIVE NOT RECRUITING
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
OHSU Knight Cancer Institute
NCT02508038 RECRUITING
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
University of Wisconsin, Madison
NCT05768932 RECRUITING
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
SillaJen, Inc.
NCT07025564 RECRUITING
MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
NCT05735184 RECRUITING
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc.
NCT03017820 RECRUITING
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
NCT06626633 ACTIVE NOT RECRUITING
2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML
University of Maryland, Baltimore
NCT07014462 ENROLLING BY INVITATION
A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML
University of Vermont
NCT06307054 RECRUITING
CLL-1 CAR-NK Cells for Relapsed/Refractory AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT07198867 RECRUITING
A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
First Affiliated Hospital of Zhejiang University
NCT05924750 RECRUITING
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05292664 ACTIVE NOT RECRUITING
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Andrew E. Place, MD
NCT06501196 RECRUITING
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
BlossomHill Therapeutics
NCT06763341 RECRUITING
A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
City of Hope Medical Center
NCT04219163 ACTIVE NOT RECRUITING
Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen
Baylor College of Medicine
NCT06994676 RECRUITING
A Study of CBX-250 in Participants With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Crossbow Therapeutics, Inc.
NCT02159495 ACTIVE NOT RECRUITING
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
City of Hope Medical Center
NCT05441514 ACTIVE NOT RECRUITING
Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
NCT06401603 RECRUITING
A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT07162116 RECRUITING
A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants
Shijiazhuang Yiling Pharmaceutical Co. Ltd
NCT02890329 ACTIVE NOT RECRUITING
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT06021600 ACTIVE NOT RECRUITING
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
M.D. Anderson Cancer Center
NCT07156435 RECRUITING
Vyxeos® With Clofarabine for Pediatric AML
Princess Maxima Center for Pediatric Oncology
NCT07109518 RECRUITING
uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Institute of Hematology & Blood Diseases Hospital, China
NCT03874052 RECRUITING
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Jennifer Saultz
NCT07137637 NOT YET RECRUITING
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Hangzhou Polymed Biopharmaceuticals, Inc.
NCT07131085 NOT YET RECRUITING
QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS)
Anhui Provincial Hospital
NCT06378437 RECRUITING
A Study of GLB-001 in Patients With Myeloid Malignancies
Hangzhou GluBio Pharmaceutical Co., Ltd.
NCT06786533 RECRUITING
Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML
Hemogenyx Pharmaceuticals LLC
NCT04375631 RECRUITING
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Fred Hutchinson Cancer Center
NCT06357182 RECRUITING
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
OHSU Knight Cancer Institute
NCT03843528 ACTIVE NOT RECRUITING
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation
Johns Hopkins All Children's Hospital
NCT03190278 ACTIVE NOT RECRUITING
Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Cellectis S.A.
NCT07106749 RECRUITING
CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
Institute of Hematology & Blood Diseases Hospital, China
NCT07107126 NOT YET RECRUITING
Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
Remedy Plan, Inc.
NCT05659732 RECRUITING
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer
PharmaEngine
NCT07094464 ACTIVE NOT RECRUITING
Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation
Daihong Liu
NCT06287944 RECRUITING
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
City of Hope Medical Center
NCT05703542 RECRUITING
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
Eric Stephen Winer, MD
NCT05857969 RECRUITING
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Florida International University
NCT04891757 ACTIVE NOT RECRUITING
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
Foghorn Therapeutics Inc.
NCT05139004 ACTIVE NOT RECRUITING
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
NCT06834282 RECRUITING
CER-1236 in Patients With Acute Myeloid Leukemia (AML)
CERo Therapeutics Holdings, Inc.
NCT06594445 RECRUITING
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
Masonic Cancer Center, University of Minnesota
NCT04603001 ACTIVE NOT RECRUITING
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Eli Lilly and Company
NCT03766126 ACTIVE NOT RECRUITING
Lentivirally Redirected CD123 Autologous T Cells in AML
University of Pennsylvania
NCT03009240 ACTIVE NOT RECRUITING
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia
City of Hope Medical Center
NCT03232268 ACTIVE NOT RECRUITING
HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies
Institut Paoli-Calmettes
NCT07020533 NOT YET RECRUITING
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT07014449 RECRUITING
Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
Hangzhou Weben Pharma Co., Ltd
NCT06880354 RECRUITING
A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
NCT02203903 RECRUITING
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
Catherine Bollard
NCT06996119 NOT YET RECRUITING
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
City of Hope Medical Center
NCT05222984 ACTIVE NOT RECRUITING
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax
City of Hope Medical Center
NCT05101551 RECRUITING
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
Norman J. Lacayo
NCT05233618 RECRUITING
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
Karen Ballen, MD
NCT05829226 RECRUITING
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
PureTech
NCT05473910 RECRUITING
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
TScan Therapeutics, Inc.
NCT05949125 RECRUITING
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
AvenCell Europe GmbH
NCT06634394 RECRUITING
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
Aptevo Therapeutics
NCT05716009 ACTIVE NOT RECRUITING
Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04013685 ACTIVE NOT RECRUITING
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc.
NCT05377827 ACTIVE NOT RECRUITING
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Washington University School of Medicine
NCT06047886 RECRUITING
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
University of Alabama at Birmingham
NCT06462365 RECRUITING
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X, Inc.
NCT02632708 ACTIVE NOT RECRUITING
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
Institut de Recherches Internationales Servier
NCT06222580 RECRUITING
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Uma Borate
NCT06399640 RECRUITING
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Vanderbilt-Ingram Cancer Center
NCT06245746 RECRUITING
UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT05947344 RECRUITING
A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)
Zhejiang ACEA Pharmaceutical Co. Ltd.
NCT05662904 NOT YET RECRUITING
Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML
German Cancer Research Center
NCT05190471 RECRUITING
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
Bio-Path Holdings, Inc.
NCT04953780 ACTIVE NOT RECRUITING
2157GCCC:Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Dx AML
West Virginia University
NCT05756777 RECRUITING
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center
NCT06820268 RECRUITING
A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies
NovaOnco Therapeutics Co., Ltd.
NCT06498973 RECRUITING
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT06737523 RECRUITING
Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML
The First Affiliated Hospital of Xiamen University
NCT06651866 RECRUITING
Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients
The First Affiliated Hospital of Xiamen University
NCT06575296 RECRUITING
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
City of Hope Medical Center
NCT05672147 RECRUITING
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
NCT06543381 RECRUITING
Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT04250051 ACTIVE NOT RECRUITING
Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia
Northwestern University
NCT04623944 ACTIVE NOT RECRUITING
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
Nkarta, Inc.
NCT06731699 RECRUITING
A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS
Chengdu FenDi Pharmaceutical Co., Ltd.
NCT05476770 RECRUITING
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
NCT06696846 NOT YET RECRUITING
CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT06690827 RECRUITING
Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN
Chongqing Precision Biotech Co., Ltd
NCT06034275 RECRUITING
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Vincerx Pharma, Inc.
NCT03927261 ACTIVE NOT RECRUITING
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS
Precigen, Inc
NCT04275518 RECRUITING
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
Ascentage Pharma Group Inc.
NCT06641648 NOT YET RECRUITING
A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined with Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.
Peking University First Hospital
NCT06550713 RECRUITING
A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT05546580 RECRUITING
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
Oryzon Genomics S.A.
NCT04365179 RECRUITING
Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML
Immune System Key Ltd
NCT06463327 NOT YET RECRUITING
ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML
TC Biopharm
NCT06441084 NOT YET RECRUITING
A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation
Nuwacell Biotechnologies Co., Ltd.
NCT05758610 RECRUITING
A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients
Shengke Pharmaceuticals (Jiangsu) Limited, China
NCT04771572 RECRUITING
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical Inc
NCT06367673 RECRUITING
Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia
Zhejiang University
NCT06347458 NOT YET RECRUITING
BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children
Guangzhou Bio-gene Technology Co., Ltd
NCT03560882 ACTIVE NOT RECRUITING
A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
Joaquina Baranda
NCT04243785 RECRUITING
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Edgewood Oncology Inc.
NCT06252584 NOT YET RECRUITING
Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients
University Hospital Tuebingen
NCT05607199 RECRUITING
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
Aurigene Discovery Technologies Limited
NCT05995028 RECRUITING
Universal 4SCAR7U Targeting CD7-positive Malignancies
Shenzhen Geno-Immune Medical Institute
NCT06049667 RECRUITING
A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies
Nanjing Chia-tai Tianqing Pharmaceutical
NCT06027853 RECRUITING
Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia
Zhejiang University
NCT05506332 RECRUITING
Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia
University Hospital, Antwerp
NCT05445011 RECRUITING
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT04167696 RECRUITING
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
Celyad Oncology SA
NCT06802523 SUSPENDED
Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT03772925 TERMINATED
Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
NCT03358719 COMPLETED
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Roswell Park Cancer Institute
NCT05170828 WITHDRAWN
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
NCT04964505 TERMINATED
Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia
Brian Jonas
NCT04915612 COMPLETED
Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT03467386 SUSPENDED
Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia
City of Hope Medical Center
NCT03600155 COMPLETED
Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT05987696 COMPLETED
Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
NCT05654779 TERMINATED
CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
NCT06492707 SUSPENDED
DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial
Fred Hutchinson Cancer Center
NCT02381548 TERMINATED
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT05787496 TERMINATED
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
NextCure, Inc.
NCT04914845 COMPLETED
KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia
University of Colorado, Denver
NCT05665530 COMPLETED
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Prelude Therapeutics
NCT04139434 COMPLETED
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
Newave Pharmaceutical Inc
NCT04230265 TERMINATED
Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
AvenCell Europe GmbH
NCT03932643 COMPLETED
ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant
University of Nebraska
NCT02312102 COMPLETED
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
NCT04220684 COMPLETED
Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML
Sumithira Vasu
NCT03042689 COMPLETED
Study of Regorafenib in Patients With Advanced Myeloid Malignancies
Massachusetts General Hospital
NCT03760523 TERMINATED
Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia
H. Lee Moffitt Cancer Center and Research Institute
NCT06399315 COMPLETED
Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers
Lomond Therapeutics Holdings, Inc.
NCT06709131 SUSPENDED
A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia
He Huang
NCT06454409 SUSPENDED
Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
NCT05400122 SUSPENDED
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
David Wald
NCT04937166 TERMINATED
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
Kahr Medical
NCT02996773 COMPLETED
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
NCT03900949 COMPLETED
Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia
Uma Borate
NCT03263936 COMPLETED
Epigenetic Reprogramming in Relapse/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
NCT04678336 TERMINATED
CD123 Redirected T Cells for AML in Pediatric Subjects
University of Pennsylvania
NCT03515512 COMPLETED
IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
NCT05155709 TERMINATED
A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.
Novartis Pharmaceuticals
NCT03940352 TERMINATED
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Novartis Pharmaceuticals
NCT04702425 TERMINATED
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
Novartis Pharmaceuticals
NCT04666649 COMPLETED
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
University of Maryland, Baltimore
NCT04609826 COMPLETED
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Janssen Research & Development, LLC
NCT05470140 COMPLETED
A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
Wugen, Inc.
NCT05961839 TERMINATED
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Schrödinger, Inc.
NCT04512105 COMPLETED
Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia
University of California, Irvine
NCT06158100 SUSPENDED
Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Antonio M Jimenez Jimenez
NCT05817058 TERMINATED
First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Affimed GmbH
NCT04789408 TERMINATED
Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia
Kite, A Gilead Company
NCT02675452 TERMINATED
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
Amgen
NCT05153330 TERMINATED
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Biomea Fusion Inc.
NCT04839341 COMPLETED
Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients
Apollomics Inc.
NCT05521087 WITHDRAWN
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
Janssen Research & Development, LLC
NCT02446964 COMPLETED
Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia
City of Hope Medical Center
NCT06128044 TERMINATED
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Caribou Biosciences, Inc.
NCT05248685 WITHDRAWN
Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Beijing Boren Hospital
NCT06572631 WITHDRAWN
Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor
City of Hope Medical Center
NCT05038800 TERMINATED
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)
Merck Sharp & Dohme LLC
NCT03063944 COMPLETED
STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03286114 TERMINATED
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
University of Michigan Rogel Cancer Center
NCT04081259 COMPLETED
LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy
Dana-Farber Cancer Institute
NCT05038644 TERMINATED
XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia
Ehab L Atallah
NCT04070768 COMPLETED
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
John Quigley
NCT03560908 WITHDRAWN
Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation
Institute of Hematology & Blood Diseases Hospital, China
NCT03813147 COMPLETED
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
NCT03755414 COMPLETED
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Washington University School of Medicine
NCT04553692 TERMINATED
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
NCT04277442 COMPLETED
Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT04477291 TERMINATED
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS
Aptose Biosciences Inc.
NCT06068868 TERMINATED
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
AbbVie
NCT02834390 COMPLETED
Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Daiichi Sankyo Co., Ltd.
NCT05548088 COMPLETED
LILRB4 STAR-T Cells in the Treatment of R/R AML/CMML
Peking University People's Hospital
NCT04372433 COMPLETED
IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML
Immune-Onc Therapeutics
NCT05275439 COMPLETED
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Shattuck Labs, Inc.
NCT03027102 COMPLETED
Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia
University Health Network, Toronto
NCT04887259 TERMINATED
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
Lava Therapeutics
NCT03194685 COMPLETED
Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Fujifilm Pharmaceuticals U.S.A., Inc.
NCT04310592 TERMINATED
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
Celularity Incorporated
NCT04526795 TERMINATED
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia
M.D. Anderson Cancer Center
NCT04755244 TERMINATED
A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)
ALX Oncology Inc.
NCT05266950 WITHDRAWN
Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia
Beijing Boren Hospital
NCT05601466 TERMINATED
Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
NCT02236013 COMPLETED
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
Astellas Pharma Global Development, Inc.
NCT02610062 TERMINATED
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
Astellas Pharma Global Development, Inc.
NCT04207190 COMPLETED
Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia
Roswell Park Cancer Institute
NCT03955783 COMPLETED
Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies
Sanjay Mohan
NCT04714372 COMPLETED
FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
NCT02864290 TERMINATED
A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
Astellas Pharma Global Development, Inc.
NCT03755154 TERMINATED
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Institut de Recherches Internationales Servier
NCT03541369 TERMINATED
Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Amgen
NCT03441048 COMPLETED
Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia
Medical College of Wisconsin
NCT05823480 WITHDRAWN
Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS
City of Hope Medical Center
NCT04827069 COMPLETED
A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)
Sunshine Lake Pharma Co., Ltd.
NCT02484391 COMPLETED
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma
Wake Forest University Health Sciences
NCT03884829 TERMINATED
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
Cyclacel Pharmaceuticals, Inc.
NCT04500587 COMPLETED
Phase 1 First in Human Study of ZN-d5 as a Single Agent
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
NCT04017546 COMPLETED
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
Cyclacel Pharmaceuticals, Inc.
NCT03530683 TERMINATED
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Pfizer
NCT03187288 COMPLETED
Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS
University Health Network, Toronto
NCT05569512 TERMINATED
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
Malika Kapadia
NCT06007911 WITHDRAWN
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Medical College of Wisconsin
NCT05326516 COMPLETED
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
Syndax Pharmaceuticals
NCT05622591 WITHDRAWN
ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML
Elucida Oncology
NCT04637009 TERMINATED
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Astex Pharmaceuticals, Inc.
NCT04155580 TERMINATED
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Astex Pharmaceuticals, Inc.
NCT03318016 TERMINATED
Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia
University of Colorado, Denver
NCT04901416 COMPLETED
Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS
Coeptis Therapeutics
NCT03198234 TERMINATED
Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders
Roncarolo, Maria Grazia, MD
NCT05933070 TERMINATED
A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML
Inmune Bio, Inc.
NCT04172844 TERMINATED
Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia
Medical College of Wisconsin
NCT04580121 COMPLETED
A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
Hoffmann-La Roche
NCT03333005 COMPLETED
Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and Neutropenia
Basilea Pharmaceutica
NCT02971397 COMPLETED
Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Wake Forest University Health Sciences
NCT03426605 COMPLETED
A Study of LAM-003 in Patients With Acute Myeloid Leukemia
OrphAI Therapeutics
NCT05720988 WITHDRAWN
Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Jonsson Comprehensive Cancer Center
NCT04478695 TERMINATED
Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia
Amgen
NCT03878524 TERMINATED
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
NCT04912063 TERMINATED
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
AbbVie
NCT03564288 COMPLETED
Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML)
Oscotec Inc.
NCT05107856 TERMINATED
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Prelude Therapeutics
NCT02367456 COMPLETED
A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients
Pfizer
NCT03833180 COMPLETED
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT04196010 TERMINATED
Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms
University of Washington
NCT05321940 WITHDRAWN
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
Juan C. Ramos, MD
NCT02543879 COMPLETED
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
Forma Therapeutics, Inc.
NCT03904251 TERMINATED
CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia
Jonsson Comprehensive Cancer Center
NCT03298984 COMPLETED
Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
Sumitomo Pharma America, Inc.
NCT02498665 COMPLETED
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
NCT03671564 COMPLETED
Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Daiichi Sankyo Co., Ltd.
NCT04075747 COMPLETED
A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia
Jazz Pharmaceuticals
NCT03690154 TERMINATED
A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
NCT02957032 TERMINATED
A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Philogen S.p.A.
NCT02649764 COMPLETED
Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT05456269 WITHDRAWN
A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS
Race Oncology Ltd
NCT02122081 COMPLETED
Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
Sumithira Vasu
NCT04402541 COMPLETED
Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome
Cleave Therapeutics, Inc.
NCT05519527 WITHDRAWN
STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis
M.D. Anderson Cancer Center
NCT04443751 COMPLETED
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Jiangsu HengRui Medicine Co., Ltd.
NCT04896112 WITHDRAWN
A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia
Lynk Pharmaceuticals Co., Ltd
NCT04679194 TERMINATED
Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT
Mana Therapeutics
NCT02882321 TERMINATED
Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT02299518 COMPLETED
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Alice Mims
NCT03904069 WITHDRAWN
Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML
Amgen
NCT05077423 TERMINATED
A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
Y-mAbs Therapeutics
NCT03236857 COMPLETED
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
AbbVie
NCT04547062 COMPLETED
Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)
Nantes University Hospital
NCT02891278 COMPLETED
Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML
Columbia University
NCT03465540 TERMINATED
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Amgen
NCT03886831 COMPLETED
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
Prelude Therapeutics
NCT05454098 COMPLETED
Clifutinib Food Effect Study in Healthy Subjects
Sunshine Lake Pharma Co., Ltd.
NCT03878927 TERMINATED
CPX-351+GO in Subjects 55 Years Old, or Older, With AML
Weill Medical College of Cornell University
NCT05513612 WITHDRAWN
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
Shanghai Pudong Hospital
NCT02890758 COMPLETED
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Brenda Cooper, MD
NCT02960646 COMPLETED
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
M.D. Anderson Cancer Center
NCT03194932 COMPLETED
Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
St. Jude Children's Research Hospital
NCT04176393 COMPLETED
A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation
CStone Pharmaceuticals
NCT05223699 TERMINATED
Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)
Magenta Therapeutics, Inc.
NCT03585517 COMPLETED
Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)
Beijing Immunochina Medical Science & Technology Co., Ltd.
NCT05518357 COMPLETED
LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Hebei Yanda Ludaopei Hospital
NCT03484520 TERMINATED
A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
AbbVie
NCT04402723 TERMINATED
Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT04543305 COMPLETED
A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
Prelude Therapeutics
NCT04038437 COMPLETED
A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML
Jazz Pharmaceuticals
NCT04022785 COMPLETED
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04496999 TERMINATED
HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.
Insel Gruppe AG, University Hospital Bern
NCT02403310 COMPLETED
A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML
H. Lee Moffitt Cancer Center and Research Institute
NCT03516760 TERMINATED
Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia
AvenCell Europe GmbH
NCT03218683 TERMINATED
Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.
AstraZeneca
NCT02698189 TERMINATED
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
Merck Sharp & Dohme LLC
NCT04272203 TERMINATED
A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
AbbVie
NCT02582359 COMPLETED
MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age
Massachusetts General Hospital
NCT03723681 COMPLETED
Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Daiichi Sankyo Co., Ltd.
NCT05001451 TERMINATED
Study of GDX012 in Patients With MRD Positive AML
GammaDelta Therapeutics Limited
NCT03848754 COMPLETED
Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Medical College of Wisconsin
NCT04655391 WITHDRAWN
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation
City of Hope Medical Center
NCT03483324 COMPLETED
Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation
Angiocrine Bioscience
NCT03552029 TERMINATED
Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)
Daiichi Sankyo
NCT02979366 COMPLETED
Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome
Institut de Recherches Internationales Servier
NCT03207191 COMPLETED
Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Philogen S.p.A.
NCT03563560 COMPLETED
A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia
Sumitomo Pharma Co., Ltd.
NCT03787498 COMPLETED
A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Opna Bio LLC
NCT03696537 TERMINATED
IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT
Naoyuki G. Saito, M.D., Ph.D.
NCT02730312 COMPLETED
PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
Xencor, Inc.
NCT03922477 TERMINATED
A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
Hoffmann-La Roche
NCT03761069 TERMINATED
Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias
PTC Therapeutics
NCT03441555 COMPLETED
A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
AbbVie
NCT03459859 COMPLETED
Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS
Justin Watts, MD
NCT03797261 TERMINATED
A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
AbbVie
NCT04973618 WITHDRAWN
Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML
Aptevo Therapeutics
NCT03519984 TERMINATED
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
University of Southern California
NCT03263637 COMPLETED
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
AstraZeneca
NCT04464889 WITHDRAWN
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Medigene AG
NCT03625505 COMPLETED
A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia
AbbVie
NCT03555955 COMPLETED
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
Jazz Pharmaceuticals
NCT02485535 COMPLETED
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
University of Chicago
NCT03790072 COMPLETED
Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML)
TC Biopharm
NCT03125876 TERMINATED
A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)
Sunshine Lake Pharma Co., Ltd.
NCT03360006 TERMINATED
A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer
AbbVie
NCT03081780 COMPLETED
Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML
Masonic Cancer Center, University of Minnesota
NCT02293993 COMPLETED
Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia
Otsuka Pharmaceutical Co., Ltd.
NCT03197714 COMPLETED
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
Hospital Universitario 12 de Octubre
NCT02750995 COMPLETED
Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML
Daniel El Fassi
NCT02750254 TERMINATED
Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Washington University School of Medicine
NCT04128020 WITHDRAWN
Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia
Sherif Farag
NCT03807063 WITHDRAWN
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT03125239 COMPLETED
Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia
Jacqueline Garcia, MD
NCT02835729 COMPLETED
A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
NewLink Genetics Corporation
NCT02779283 COMPLETED
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
NCT03661515 COMPLETED
Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML
PETHEMA Foundation
NCT02573363 COMPLETED
Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
University of Chicago
NCT02109627 TERMINATED
Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
C. Babis Andreadis
NCT02892318 COMPLETED
A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)
Hoffmann-La Roche
NCT02316964 COMPLETED
Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Sumithira Vasu
NCT03135028 TERMINATED
Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults
Gilead Sciences
NCT02875093 TERMINATED
Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML
Polaris Group
NCT03106428 COMPLETED
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
MedImmune LLC
NCT02588092 TERMINATED
Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)
ADC Therapeutics S.A.
NCT02995655 COMPLETED
CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Washington University School of Medicine
NCT02391480 COMPLETED
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
AbbVie
NCT02954653 TERMINATED
A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia
Pfizer
NCT03483948 TERMINATED
Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia
Hutchison Medipharma Limited
NCT02909972 COMPLETED
Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Aileron Therapeutics, Inc.
NCT03126864 TERMINATED
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT03612739 WITHDRAWN
EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2
Celyad Oncology SA
NCT03672851 TERMINATED
Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia
Second Affiliated Hospital of Xi'an Jiaotong University
NCT02674763 COMPLETED
Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia
ImmunoGen, Inc.
NCT03395873 TERMINATED
Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy
Milton S. Hershey Medical Center
NCT03735446 TERMINATED
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
Dana-Farber Cancer Institute
NCT02920541 COMPLETED
Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome
Institut de Recherches Internationales Servier
NCT03752138 WITHDRAWN
TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT02749708 TERMINATED
Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02826642 WITHDRAWN
A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia
Novartis Pharmaceuticals
NCT02492737 COMPLETED
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
Agios Pharmaceuticals, Inc.
NCT02678338 COMPLETED
CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies
Gilead Sciences
NCT01849276 TERMINATED
Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML
Northwestern University
NCT02323607 COMPLETED
Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations
Bhavana Bhatnagar
NCT02676323 TERMINATED
Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
St. Jude Children's Research Hospital
NCT02728700 TERMINATED
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
Stanford University
NCT03491579 WITHDRAWN
Epacadostat, Cladribine and Cytarabine (ECC) in AML
Insel Gruppe AG, University Hospital Bern
NCT03444649 WITHDRAWN
Epacadostat, Idarubicin and Cytarabine (EIC) in AML
Insel Gruppe AG, University Hospital Bern
NCT02203825 COMPLETED
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
Celyad Oncology SA
NCT02635074 TERMINATED
Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Steven E. Coutre
NCT02848248 TERMINATED
A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia
Seagen Inc.
NCT02905994 WITHDRAWN
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
Massachusetts General Hospital
NCT02680951 WITHDRAWN
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
Emory University
NCT03347994 WITHDRAWN
Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia
Justin Watts
NCT02335814 TERMINATED
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
RAPT Therapeutics, Inc.
NCT02270788 COMPLETED
Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies
St. Jude Children's Research Hospital
NCT02255162 TERMINATED
Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML
Massachusetts General Hospital
NCT01483274 WITHDRAWN
Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation
University of Louisville
NCT02791919 WITHDRAWN
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT02528877 WITHDRAWN
Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis
City of Hope Medical Center
NCT06370000 RECRUITING
Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality
Virginia Commonwealth University
NCT07044687 RECRUITING
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
AbbVie
NCT05144243 ACTIVE NOT RECRUITING
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
AbbVie
NCT06763666 NOT YET RECRUITING
CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML
Nanfang Hospital, Southern Medical University
NCT06571825 RECRUITING
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
He Huang
NCT02926586 COMPLETED
Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT03176849 COMPLETED
A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT
Phoenix Children's Hospital
Data: ClinicalTrials.gov